Generate a tailored SOP for Dr. Anders Bach. Improve your application with a focused, well-structured draft.
Anders Bach is a Professor in Medicinal Chemistry at the University of Copenhagen, where he leads the Bach Group in the Department of Drug Design and Pharmacology. He obtained his Ph.D. in Medicinal Chemistry in 2009 from the University of Copenhagen, focusing on the development of compounds targeting PDZ domains involved in protein-protein interactions. Following his postdoctoral research at the University of Copenhagen and the Italian Institute of Technology, he established his own research group in 2016, emphasizing fragment-based drug discovery (FBDD) for developing small-molecule inhibitors targeting protein-protein interactions relevant to diseases such as cancer and inflammation. In 2023, he was appointed as a Professor and continues to contribute to the scientific community through teaching and research in drug discovery. Dr. Bach is also a co-founder of Avilex Pharma, a company dedicated to developing innovative therapeutic solutions for ischemic strokes, anchored by his significant contributions in medicinal chemistry research and development.
University of Copenhagen • Copenhagen, Denmark
Leading the Bach Group in the Department of Drug Design and Pharmacology.
University of Copenhagen • Copenhagen, Denmark
Led research on small-molecule inhibitors for protein interactions.
University of Copenhagen • Copenhagen, Denmark
Engaged in teaching and research in medicinal chemistry.
Italian Institute of Technology • Genoa, Italy
Worked on small-molecule inhibitors in lipid metabolism.
University of Copenhagen • Copenhagen, Denmark
Focused on the Chemical Biology group.
University of Copenhagen • Copenhagen, Denmark
Conducted research in the Chemical Biology group.
Focuses on clinical, social, and cognitive psychology.